Your guide to IBD novel treatments and assessment tools
UEG Week 2018 saw a host of insights and symposia surrounding the assessment and treatment of Irritable Bowl Disease (IBD). Our expert faculty explored these recent advances and looked at the potential impact that biosimilars could have. Below is a round up of some of the key findings for you to explore for free at your own convenience.
New assessment tools in IBD may change your clinical practice. In this educational symposium 'Current IBD Management Strategies: Role of disease assessment' our expert faculty discuss assessment tools including the IBD index, and more. Watch the symposium here
Bitesize expert opinion
Hear from Dr Krisztina Gecse, distilling best practice use of currently available assessment tools, the role that biomarkers can play, and the potential of biosimilars to alter the current treatment paradigm. Watch the interviews
The view from UEG Week 2018
Review the report and analysis from a packed UEGW Vienna as we present daily reviews compiled by our team of scientific writers. Read the reports here
Related news and insights
Galapagos announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies, which are part of the Phase III clinical program for Jyseleca (filgotinib), for the treatment of patients with moderately to severely active Ulcerative Colitis.
Celltrion Healthcare announced two data sets relating to the use of the subcutaneous formulation of infliximab, Remsima SC (CT-P13 SC), in inflammatory bowel disease (IBD).
Developed by EPG Health for Medthority in collaboration with Biogen®. This content is intended for healthcare professionals only, and it has been funded and reviewed by Biogen® for scientific accuracy.